dronabinol has been researched along with Alzheimer Disease in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (13.04) | 18.2507 |
| 2000's | 6 (26.09) | 29.6817 |
| 2010's | 6 (26.09) | 24.3611 |
| 2020's | 8 (34.78) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, B; Cai, J; Cao, C; Gordon, M; Hong, Y; Li, M; Lin, X; Morgan, D; Shen, N; Wang, Y; Yan, J; Zhang, X; Zhou, Q | 1 |
| Brown, B; Cao, C; Chang, P; Fihurka, O; Gordon, MN; Hong, Y; Lin, X; Morgan, D; Shen, N; Wang, Y; Yan, J; Zhao, H; Zhou, Q | 1 |
| Bentulila, Z; Break, EP; David, D; Doron, R; Ellenbogen, L; Franko, M; Nitzan, K; Sarne, Y; Shamir, A; Zoharetz, M | 1 |
| Choi, P; Ham, J; Kim, J; Kim, JC; Kim, T; Park, YT | 1 |
| Hřib, R; Landa, L; Slíva, J; Šulcová, A; Trojan, V | 1 |
| Andreazza, AC; Black, SE; Gallagher, D; Herrmann, N; Kiss, A; Lanctôt, KL; Ruthirakuhan, M; Verhoeff, NPLG | 2 |
| Baldasso, GM; Bicca, MA; Capasso, R; Dutra, RC; Gonçalves, ECD; Paes, RS | 1 |
| Cooray, R; Gupta, V; Suphioglu, C | 1 |
| Calabrese, EJ; Rubio-Casillas, A | 1 |
| Black, SE; Gallagher, D; Herrmann, N; Kiss, A; Lanctôt, KL; Ruthirakuhan, M; Verhoeff, NPLG | 1 |
| Amjad, H; Burhanullah, MH; Forester, BP; Monette, PJ; Outen, JD; Rosenberg, PB; Vandrey, R | 1 |
| Cimander, KF; Emrich, HM; Müller-Vahl, KR; Schlimme, J; Schneider, U; Seifert, J | 1 |
| Andrés-Benito, P; Aso, E; Carmona, M; Ferrer, I; Maldonado, R | 1 |
| Cairns, R; Howard, R; Krishnan, S | 1 |
| Bromley-Brits, K; Cai, F; Chen, B; He, G; Song, W; Zhang, X | 1 |
| Blázquez, C; de Ceballos, ML; Gómez del Pulgar, T; Guzmán, M; Ramírez, BG | 1 |
| Eichmann, U; Kunz, D; Mahlberg, R; Walther, S | 1 |
| Campbell, VA; Gowran, A | 1 |
| Passmore, MJ | 1 |
| McLaughlin, J; Morris, J; Stelly, M; Volicer, BJ; Volicer, L | 1 |
| Volicer, L | 1 |
9 review(s) available for dronabinol and Alzheimer Disease
| Article | Year |
|---|---|
The Main Therapeutic Applications of Cannabidiol (CBD) and Its Potential Effects on Aging with Respect to Alzheimer's Disease.
Topics: Alzheimer Disease; Cannabidiol; Cannabinoids; Dronabinol; Humans | 2023 |
Agitation, Oxidative Stress, and Cytokines in Alzheimer Disease: Biomarker Analyses From a Clinical Trial With Nabilone for Agitation.
Topics: Aged; Alzheimer Disease; Biomarkers; Cognition; Cytokines; Dronabinol; Female; Humans; Male; Oxidative Stress; Psychomotor Agitation | 2020 |
Terpenoids, Cannabimimetic Ligands, beyond the
Topics: Alzheimer Disease; Anxiety; Bicyclic Monoterpenes; Cannabidiol; Cannabinoid Receptor Agonists; Cannabis; Cognitive Dysfunction; Dronabinol; Humans; Inflammatory Bowel Diseases; Neuralgia; Neuroprotective Agents; Nootropic Agents; Schizophrenia; Sesquiterpenes; Terpenes | 2020 |
Current Aspects of the Endocannabinoid System and Targeted THC and CBD Phytocannabinoids as Potential Therapeutics for Parkinson's and Alzheimer's Diseases: a Review.
Topics: Alzheimer Disease; Animals; Cannabidiol; Dronabinol; Endocannabinoids; Humans; Inflammation; Parkinson Disease | 2020 |
Biphasic effects of THC in memory and cognition.
Topics: Age Factors; Alzheimer Disease; Animals; Cognition; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Hippocampus; Humans; Marijuana Smoking; Memory Disorders; Memory, Short-Term; Neurogenesis; Nootropic Agents; Receptor, Cannabinoid, CB1 | 2018 |
[Dronabinol in neuropsychiatric diseases].
Topics: Alzheimer Disease; Analgesics, Non-Narcotic; Dronabinol; Humans; Nervous System Diseases; Neurologic Examination; Neuromuscular Diseases; Phytotherapy; Plant Extracts; Treatment Outcome | 2004 |
Cannabinoids for the treatment of dementia.
Topics: Alzheimer Disease; Cannabinoids; Dementia; Dronabinol; Humans; Psychotropic Drugs | 2009 |
Alzheimer's disease; taking the edge off with cannabinoids?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cannabinoids; Cholinesterase Inhibitors; Dronabinol; Humans; Models, Biological; Phosphorylation; tau Proteins | 2007 |
Tube feeding in Alzheimer's disease is avoidable.
Topics: Alzheimer Disease; Antidepressive Agents; Contraindications; Depression; Dronabinol; Eating; Enteral Nutrition; Humans; Psychotropic Drugs; Sertraline; Weight Loss | 1998 |
3 trial(s) available for dronabinol and Alzheimer Disease
| Article | Year |
|---|---|
Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Cognition; Double-Blind Method; Dronabinol; Female; Homes for the Aged; Humans; Male; Nursing Homes; Psychiatric Status Rating Scales; Treatment Outcome | 2019 |
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Dementia, Vascular; Dronabinol; Electroencephalography; Female; Hallucinogens; Humans; Male; Motor Activity; Pilot Projects; Psychomotor Agitation; Sleep Wake Disorders | 2006 |
Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Anorexia; Antidepressive Agents; Antipsychotic Agents; Appetite Stimulants; Behavioral Symptoms; Cross-Over Studies; Dronabinol; Drug Therapy, Combination; Female; Humans; Longitudinal Studies; Male; Severity of Illness Index; Time Factors; Treatment Outcome; Weight Gain | 1997 |
11 other study(ies) available for dronabinol and Alzheimer Disease
| Article | Year |
|---|---|
Low-Dose Delta-9-Tetrahydrocannabinol as Beneficial Treatment for Aged APP/PS1 Mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Disease Models, Animal; Dronabinol; Glycogen Synthase Kinase 3 beta; Maze Learning; Mice; Mice, Transgenic; Presenilin-1 | 2022 |
The Memory Benefit to Aged APP/PS1 Mice from Long-Term Intranasal Treatment of Low-Dose THC.
Topics: Administration, Intranasal; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Disease Models, Animal; Dronabinol; Mice; Mice, Inbred C57BL; Mice, Transgenic; Presenilin-1 | 2022 |
An Ultra-Low Dose of ∆9-Tetrahydrocannabinol Alleviates Alzheimer's Disease-Related Cognitive Impairments and Modulates TrkB Receptor Expression in a 5XFAD Mouse Model.
Topics: Alzheimer Disease; Animals; Cognitive Dysfunction; Disease Models, Animal; Dronabinol; Mice; Mice, Transgenic; Receptor, trkB | 2022 |
The Cannabinoids, CBDA and THCA, Rescue Memory Deficits and Reduce Amyloid-Beta and Tau Pathology in an Alzheimer's Disease-like Mouse Model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cannabidiol; Cannabinoids; Cannabis; Dronabinol; Memory Disorders; Mice; Neuroprotective Agents | 2023 |
Tetrahydrocannabinol Has Potential for Treating Agitation in Alzheimer's Disease.
Topics: Aggression; Alzheimer Disease; Dronabinol; Humans; Psychomotor Agitation | 2019 |
24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with Nabilone.
Topics: Aged, 80 and over; Alzheimer Disease; Anti-Anxiety Agents; Cross-Sectional Studies; Dronabinol; Female; Humans; Hydroxycholesterols; Longitudinal Studies; Male; Psychomotor Agitation; Treatment Outcome | 2019 |
Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cannabidiol; Cognition; Disease Models, Animal; Dronabinol; Humans; Male; Medical Marijuana; Memory; Mice, Inbred C57BL; Mice, Transgenic; Nootropic Agents; Presenilin-1; Random Allocation; Receptor, Cannabinoid, CB2; tau Proteins; Treatment Outcome | 2016 |
Effect of synthetic cannabinoid HU210 on memory deficits and neuropathology in Alzheimer's disease mouse model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Brain; Cannabinoid Receptor Modulators; Cognition Disorders; Conditioning, Psychological; Disease Models, Animal; Dronabinol; Female; Humans; Male; Maze Learning; Memory; Memory Disorders; Mice; Mice, Transgenic; Neuroprotective Agents; Plaque, Amyloid; Treatment Failure | 2010 |
Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzoxazines; Cannabinoids; Cells, Cultured; Coculture Techniques; Dronabinol; Female; Humans; Injections, Intraventricular; Male; Maze Learning; Microglia; Middle Aged; Morpholines; Motor Activity; Naphthalenes; Nerve Degeneration; Neurons; Neuroprotective Agents; Nitric Oxide; Peptide Fragments; Plaque, Amyloid; Protein Processing, Post-Translational; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Signal Transduction; Tumor Necrosis Factor-alpha | 2005 |
The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation.
Topics: Aged; Alzheimer Disease; Anti-Anxiety Agents; Dronabinol; Humans; Male; Psychomotor Agitation; Treatment Outcome | 2008 |
Dronabinol in Alzheimer's disease.
Topics: Alzheimer Disease; Anorexia; Appetite Stimulants; Dronabinol; Humans | 1998 |